Sunho Biologics gets green light for downsized IPO
The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing Key Takeaways: Sunho Biologics has no revenue or…
Recent Articles
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK -
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- BRIEF: Mixue’s Hong Kong IPO gets green light from China’s securities regulator
